Modeling the Prediction on the Efficacy of a Homologous Third Dose of CoronaVac Against SARS-CoV-2 Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 — China, 2020–2021

作     者：Xinhua Chen Xufang Bai Xinghui Chen Nan Zheng Juan Yang Juanjuan Zhang Hongjie Yu 

作者机构：School of Public HealthFudan UniversityKey Laboratory of Public Health SafetyMinistry of EducationShanghai MunicipalityChina Shanghai Huashen Institute of Microbes and InfectionsShanghai MunicipalityChina Shanghai Institute of Infectious Disease and BiosecurityFudan UniversityShanghai MunicipalityChina 

出 版 物：《China CDC weekly》 (中国疾病预防控制中心周报（英文）)

年 卷 期：2023年第5卷第5期

页      面：103-107,I0006页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by the Key Program of the National Natural Science Foundation of China(82130093) Shanghai Municipal Science and Technology Major Project(HS2021SHZX001) 

主　　题：vaccine acute respiratory 

摘      要：Summary What is already known about this topic?Previous studies have reported vaccine efficacy or effectiveness against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron subvariants for several vaccine ***,there are currently few data on estimates of inactivated platform coronavirus disease 2019(COVID-19)vaccines,especially against the globally dominant subvariant—Omicron BA.5.